Endomag was founded to solve cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.
The company’s first product, the Sentimag®, is an ultrasensitive hand-held probe for tracking Sienna+® - an injectable tracer used in sentinel lymph node biopsy (SLNB), currently the standard of care in tracking the spread of breast cancer. By avoiding the need for radioisotopes, the availability of SLNB is significantly extended. At present, as many as half of the patients in the West who would benefit from the SLNB technique are not able to access it, and availability is much worse still in other parts of the world.
The Sentimag® is an ultrasensitive hand-held probe for detecting magnetic tracers in the human body. By tracking the presence of injected Sienna+®, the Sentimag® can be used to locate lymph nodes in the treatment of cancer.
Endomags’ development of the Sentimag® and Sienna+® system allows best practice SLNB to be performed anywhere, by any practitioner, without substantially changing their working practice. The combined system offers reduced workflow complexity with a corresponding reduction in procedural cost. The complete system is CE-approved.